LYMPHAZURIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lymphazurin, and when can generic versions of Lymphazurin launch?
Lymphazurin is a drug marketed by Covidien and is included in one NDA.
The generic ingredient in LYMPHAZURIN is isosulfan blue. There are six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the isosulfan blue profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lymphazurin
A generic version of LYMPHAZURIN was approved as isosulfan blue by MYLAN INSTITUTIONAL on July 20th, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LYMPHAZURIN?
- What are the global sales for LYMPHAZURIN?
- What is Average Wholesale Price for LYMPHAZURIN?
Summary for LYMPHAZURIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 41 |
| Clinical Trials: | 10 |
| Patent Applications: | 282 |
| What excipients (inactive ingredients) are in LYMPHAZURIN? | LYMPHAZURIN excipients list |
| DailyMed Link: | LYMPHAZURIN at DailyMed |
Recent Clinical Trials for LYMPHAZURIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Navidea Biopharmaceuticals | Phase 1 |
| Cardinal Health 414, LLC | Phase 1 |
| University of California, San Diego | Phase 1 |
US Patents and Regulatory Information for LYMPHAZURIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covidien | LYMPHAZURIN | isosulfan blue | SOLUTION;SUBCUTANEOUS | 018310-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
